Obstructive sleep apnea (OSA)-related excessive daytime sleepiness (EDS) is about more than being sleepy. OSA-related EDS has been shown to impact work performance, work presenteeism and absenteeism, cognitive dysfunction, physical health, and functioning, occupational and driving accidents, personal relationships, and subsequently health-related quality of life (HRQoL). Despite these burdens, many patients do not seek treatment, often owing to beliefs and attitudes about the need to address these issues with a medical provider in order to seek treatment. Clinicians and patients both need to appreciate the HRQoL and functional impact of OSA-related EDS and thereby the need for early, effective treatment.
Join Drs. Richard Bogan and Terri Weaver as they discuss case 1 of this 3-part CMEO BriefCase series and provide insight into the extensive impact of OSA-related EDS on psychosocial functioning and HRQoL to promote the need for early intervention.
At the end of this CME/CE activity, participants should be able to recognize the impact and burden of OSA-related EDS on HRQoL and work productivity.
This program is supported by an independent medical education grant from Jazz Pharmaceuticals.
Physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in sleep, pulmonology, psychiatry, neurology and/or primary care
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Bogan reports the following financial relationships: Consultant: Harmony Biosciences, LLC; Jazz Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc. Grants: Axsome Therapeutics, Inc.; Eisai Inc.; Flamel Technologies; Fresca Medical, Inc.; Harmony Biosciences, LLC; Idorsia Pharmaceuticals; Jazz Pharmaceuticals, Inc.; Merck & Co., Inc.; Philips; Suven Life Sciences; and Takeda Pharmaceuticals U.S.A., Inc. Speakers Bureau: Eisai Inc.; Harmony Biosciences, LLC; and Jazz Pharmaceuticals, Inc.
Dr. Weaver reports the following financial relationships: Advisory Board: Jazz Pharmaceuticals, Inc. Other financial support: Bayer AG; Cook Medical; Evidation Health; Functional Outcomes of Sleep Questionnaire (FOSQ) Instrument Licensing Agreement; Jazz Pharmaceuticals, Inc.; LivaNova PLC; Nyxoah SA; Philips Philips Resphonics; ResMed; ResMed Germany; RWS; Stratevi; Verily; and WCG MedAvante-ProPhase, Inc.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-21-062-H02-P.
Call us at 877.CME.PROS (877.263.7767).